Creative Medical Technology Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CELZ research report →
Price Chart
About the company
Creative Medical Technology Holdings, Inc. , a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology.
- CEO
- Timothy Warbington
- IPO
- 2015
- Employees
- 4
- HQ
- Phoenix, AZ, US
Get TickerSpark's AI analysis on CELZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.32M
- P/E
- -0.45
- Fwd P/E
- 0.28
- PEG
- -0.01
- P/S
- 774.54
- P/B
- 0.39
- EV/EBITDA
- 1.05
- Div Yield
- 0.00%
- Gross Margin
- -1732.37%
- Op Margin
- -208004.40%
- Net Margin
- -201355.37%
- ROE
- -86.70%
- ROIC
- -71.90%
Latest fiscal year · YoY change
- Revenue
- $6.00K-45.5%
- Gross Profit
- $3.81K-42.3%
- Op Income
- $-6,142,814
- Net Income
- $-5,995,008-9.1%
- EPS
- $-2.52+32.1%
- OCF Growth
- -10.5%
- FCF Growth
- -10.5%
- 52W High
- $6.25
- 52W Low
- $0.62
- 50D MA
- $1.01
- 200D MA
- $1.70
- Beta
- 1.90
- RSI (14)
- 42
- Avg Volume
- 6.89M
No earnings-call transcripts are available for CELZ yet.
- Free Float
- 92.4%
- Shares Outstanding
- 2.58M
- Float Shares
- 2.38M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 6 ETFs
Biggest fund positions in CELZ by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 24, 26 | Warbington Timothy | other | 1,000,000 |
| Feb 18, 25 | Finger Michael H. | sell | 750 |
| Feb 19, 25 | Finger Michael H. | sell | 750 |
| Jun 28, 23 | Warbington Timothy | buy | 200 |
| Jun 27, 23 | Warbington Timothy | buy | 200 |
| Jun 27, 23 | Warbington Timothy | buy | 300 |
| Jun 27, 23 | Warbington Timothy | buy | 300 |
| Nov 22, 22 | Warbington Timothy | buy | 200 |
| Nov 22, 22 | Warbington Timothy | buy | 9,800 |
| Nov 21, 22 | Warbington Timothy | buy | 5,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CELZ coverage
Recent articles, reports, and earnings notes.
No research on CELZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CELZ report →Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
defenseworld.net · Sep 30
Creative Medical Technology (NASDAQ:CELZ) & argenex (NASDAQ:ARGX) Head to Head Analysis
defenseworld.net · Sep 25
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
globenewswire.com · Sep 17
Critical Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. CRISPR Therapeutics (NASDAQ:CRSP)
defenseworld.net · Sep 8
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
globenewswire.com · Aug 20
Creative Medical Technology Stock Surges After Key Patent Win
benzinga.com · Aug 6
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
globenewswire.com · Aug 6
Creative Medical Technology Holdings Issues Mid-Year Update
globenewswire.com · Jul 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.